何时多多益善：额外初始治疗在肺动脉高压中的作用
When more is more: the role of additional upfront therapy in pulmonary arterial hypertension.
作者信息
Niedermeyer Shannon, Hassoun Paul
机构信息
Division of Pulmonary and Critical Care Medicine, Department of Medicine, Johns Hopkins University, Baltimore, MD, USA.
出版信息
ERJ Open Res. 2023 Jan 16;9(1). doi: 10.1183/23120541.00592-2022. eCollection 2023 Jan.
相似文献
1
When more is more: the role of additional upfront therapy in pulmonary arterial hypertension.何时多多益善：额外初始治疗在肺动脉高压中的作用
ERJ Open Res. 2023 Jan 16;9(1). doi: 10.1183/23120541.00592-2022. eCollection 2023 Jan.
2
Combination Therapy in Pulmonary Arterial Hypertension-Targeting the Nitric Oxide and Prostacyclin Pathways.肺动脉高压的联合治疗-靶向一氧化氮和前列环素通路。
J Cardiovasc Pharmacol Ther. 2021 Sep;26(5):453-462. doi: 10.1177/10742484211006531. Epub 2021 Apr 9.
3
Strategies for optimizing intravenous prostacyclin-analog therapy in patients with pulmonary arterial hypertension.优化肺动脉高压患者静脉注射前列环素类似物治疗的策略
Expert Rev Respir Med. 2022 Jan;16(1):57-66. doi: 10.1080/17476348.2022.2011220. Epub 2021 Dec 8.
4
Effectiveness and Outcome of Pulmonary Arterial Hypertension-Specific Therapy in Japanese Patients With Pulmonary Arterial Hypertension.肺动脉高压特异性治疗在日本肺动脉高压患者中的疗效和结局。
Circ J. 2017 Dec 25;82(1):275-282. doi: 10.1253/circj.CJ-17-0139. Epub 2017 Jul 26.
5
Additional Use of Prostacyclin Analogs in Patients With Pulmonary Arterial Hypertension: A Meta-Analysis.前列环素类似物在肺动脉高压患者中的额外应用：一项荟萃分析。
Front Pharmacol. 2022 Feb 9;13:817119. doi: 10.3389/fphar.2022.817119. eCollection 2022.
6
Upfront triple oral combination therapy including selexipag in a high-risk patient with idiopathic pulmonary arterial hypertension: a case report.在一名特发性肺动脉高压高危患者中使用包括司来帕格在内的初始三联口服联合疗法：病例报告
Eur Heart J Case Rep. 2020 Aug 30;4(5):1-5. doi: 10.1093/ehjcr/ytaa190. eCollection 2020 Oct.
7
The role of combination therapy in managing pulmonary arterial hypertension.联合治疗在肺动脉高压管理中的作用。
Eur Respir Rev. 2014 Dec;23(134):469-75. doi: 10.1183/09059180.00007314. Epub 2014 Dec 1.
8
Combination therapy in pulmonary arterial hypertension: recent accomplishments and future challenges.肺动脉高压的联合治疗：近期成果与未来挑战
Pulm Circ. 2017 Apr-Jun;7(2):312-325. doi: 10.1177/2045893217710639. Epub 2017 May 30.
9
Prostacyclin therapy for pulmonary arterial hypertension: new directions.前列环素治疗肺动脉高压：新方向
Semin Respir Crit Care Med. 2005 Aug;26(4):394-401. doi: 10.1055/s-2005-916154.
10
Diagnosis and Treatment of Pulmonary Arterial Hypertension: A Review.肺动脉高压的诊断与治疗：综述
JAMA. 2022 Apr 12;327(14):1379-1391. doi: 10.1001/jama.2022.4402.
本文引用的文献
1
Early selexipag initiation and long-term outcomes: insights from randomised controlled trials in pulmonary arterial hypertension.司来帕格早期启用与长期预后：肺动脉高压随机对照试验的见解
ERJ Open Res. 2023 Jan 16;9(1). doi: 10.1183/23120541.00456-2022. eCollection 2023 Jan.
2
2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension.2022年欧洲心脏病学会/欧洲呼吸学会肺动脉高压诊断和治疗指南。
Eur Respir J. 2023 Jan 6;61(1). doi: 10.1183/13993003.00879-2022. Print 2023 Jan.
3
Pulmonary Arterial Hypertension.肺动脉高压
N Engl J Med. 2021 Dec 16;385(25):2361-2376. doi: 10.1056/NEJMra2000348.
4
Three- Versus Two-Drug Therapy for Patients With Newly Diagnosed Pulmonary Arterial Hypertension.三药治疗与两药治疗新发肺动脉高压患者的疗效比较。
J Am Coll Cardiol. 2021 Oct 5;78(14):1393-1403. doi: 10.1016/j.jacc.2021.07.057.
5
Association between Initial Treatment Strategy and Long-Term Survival in Pulmonary Arterial Hypertension.初始治疗策略与肺动脉高压长期生存的关系。
Am J Respir Crit Care Med. 2021 Oct 1;204(7):842-854. doi: 10.1164/rccm.202009-3698OC.
6
Sotatercept for the Treatment of Pulmonary Arterial Hypertension.索他拉特塞治疗肺动脉高压。
N Engl J Med. 2021 Apr 1;384(13):1204-1215. doi: 10.1056/NEJMoa2024277.
7
Relationship Between Time From Diagnosis and Morbidity/Mortality in Pulmonary Arterial Hypertension: Results From the Phase III GRIPHON Study.肺动脉高压发病与发病率/死亡率之间的关系：来自 III 期 GRIPHON 研究的结果。
Chest. 2021 Jul;160(1):277-286. doi: 10.1016/j.chest.2021.01.066. Epub 2021 Feb 3.
8
Knockdown of bone morphogenetic protein type II receptor leads to decreased aquaporin 1 expression and function in human pulmonary microvascular endothelial cells.骨形态发生蛋白 II 型受体敲低导致人肺微血管内皮细胞水通道蛋白 1 的表达和功能降低。
Can J Physiol Pharmacol. 2020 Nov;98(11):834-839. doi: 10.1139/cjpp-2020-0185. Epub 2020 Jul 20.
9
Medication dosing for heart failure with reduced ejection fraction - opportunities and challenges.心力衰竭伴射血分数降低患者的药物剂量调整——机遇与挑战。
Eur J Heart Fail. 2019 Mar;21(3):286-296. doi: 10.1002/ejhf.1351. Epub 2018 Dec 10.
10
Pulmonary arterial hypertension: pathogenesis and clinical management.肺动脉高压：发病机制与临床管理
BMJ. 2018 Mar 14;360:j5492. doi: 10.1136/bmj.j5492.
Zotero 插件